Liminatus Pharma, a clinical-stage biopharmaceutical company, agreed to go public via a SPAC merger with Arrow Capital-backed Iris Acquisition, a publicly traded special purpose acquisition company, in a $334m deal. “The agreement with Iris and the treatments we are now set to develop which have originated from leading global cancer scientists at the Thomas Jefferson University in the US and from Innobation in South Korea, will be a game changer for this area of the healthcare market. There is a significant unmet need for improved treatment for the cancer indications we are targeting, and with the increased capital, we are hopeful that the timelines for getting these potentially life-saving medicines to market have been accelerated,” Chris Kim, Liminatus CEO.